📢Coming hot off the press🔥 Check out and enjoy the latest issue of the MJR 👉mjrheum.org

EULAR recommendations for the management of systemic lupus erythematosus: 2023 update 🔴 HCQ for all 5 mg/kg/day 🔴 GC as ‘bridging therapy’ or maintenance ≤ 5 mg/day 🔴 Prompt initiation of immunosuppressive and/or biological agents EULAR 👉 bit.ly/45ulfyD

Absolutely delighted to share the EULAR 2023 Recommendations for the Management of #SLE 🚨 It was an immense honour to be invited to join the task force authoring this work 💡 Key highlights 1️⃣ Early intervention 2️⃣ Minimise steroids 3️⃣ Nephritis ard.bmj.com/content/annrhe…

Pragmatic targets for moderate/severe SLE and implications for clinical care and trial design: ▶️ Sustained DORIS or LLDAS for at least 6 m is sufficient ▶️While their attainment for at least 24 m ensures high specificity for damage-free progression 👉 bit.ly/3Ofw2am

Distinct long-term disease activity trajectories differentiate early on treatment with etanercept in both rheumatoid arthritis and spondylarthritis patients: a prospective cohort study George Bertsias George Fragoulis Olena Zimba Nelly ZIADE 🍀 Tsvetoslav Georgiev link.springer.com/article/10.100…

A path to Glucocorticoid Stewardship: a critical review of clinical recommendations for the treatment of systemic l… pubmed.ncbi.nlm.nih.gov/38281071/

#lupus in #male nice talk by ⁦George Bertsias⁩ #lupus2024

Final remarks from Dr George Bertsias on #SLE in men. #Lupus2024

TRAINING BURSARY PROGRAMME 2024 ‼️ APPLICATIONS for the fourth edition of this important initiative dedicated to physicians under 40 are now OPEN! ☑️ Deadline: 31st May 2024 ⏰ Discover more: sleuro.org/the-program/ Download the Application form: d10qmes3r0zm40.cloudfront.net/sleuro/wp-cont…

Disentangling the riddle of #SLE with #APS Blood transcriptome analysis reveals a less pronounced IFN-signature and distinct molecular profiles in venous versus arterial events 🔬 Whole-blood RNA-sequencing ⭐ 299 SLE (108 SLE-aPL+) ⭐72 matched HC 👉 bit.ly/3PWPgCb

🎙️ New @ARD_BMJ #podcast! 🦋 Go over the 2023 EULAR #SLE recommendations with leading authors A.Fanouriakis & D.Boumpas 🎧 bit.ly/4bgIy2s George Bertsias Chris Wincup Ioannis Parodis Laurent ARNAUD Lupus Europe Maria Tektonidou Ian N Bruce Marta Mosca

🦋 Not every malar rash is SLE 🫷

Achievable but elusive: LLDAS and DORIS remission in clinical trials of #belimumab Linked Comment by George Bertsias & Jinoos Yazdany thelancet.com/journals/lanrh… #SLE

Interested in #systemic #lupus erythematosus? Check out our #systematicreview informing the latest EULAR recommendations ▶️ new areas: use of type I IFN inhibitors (non-renal), belimumab (nephritis), tapering for remission & low activity targets 🔗bit.ly/3Ucmr6W

Molecular basis for the disease-modifying effects of #belimumab in #lupus: ✅ neutrophil degranulation, type I interferon signalling and cytokine production👉 good response ❌cell cycle checkpoints, PI3K/Akt and TGF-beta signalling pathways👉bad response ard.bmj.com/content/early/…

Happy to share our review on female predominance in SLE kwnsfk27.r.eu-west-1.awstrack.me/L0/https:%2F%2…

✅ Let's see who will bring forward the best arguments 😏😇 #Lupus nephritis - standard of care (for all, will already be something)

Happy to share our collaborative work with friends and colleagues from Ferrara rmdopen.bmj.com/content/11/1/e…

🤔What's the role of #Lupus serology in the #T2T strategy? My opinion: it's off target🎯but still relevant to the treat-to-target strategy in #SLE Find out why in this #editorial published in Rheumatology & Rheumatology Advances in Practice : academic.oup.com/rheumatology/a…

📢Join the QoC Committee Webinar: "How to manage rheumatic diseases during conception, pregnancy and lactation". 💻Tuesday 30 September 2025, 17:00 - 18:00 CEST Register here: pulse.ly/jnb48vcax9 #EULAR #Rheumatology #eularEDUCATION #QoC